The archive · Health & Care · Financial decision · 2025–2026
Lunit bets a final ₩250B rights issue clears its Volpara debt
Lunit's Volpara deal left ₩197B of put-option risk; its fix — a 'final' ₩250B rights issue plus a profitability pivot — drew 104.7% shareholder take-up.
Lunit
What the business is
Lunit sells AI for cancer care: Lunit INSIGHT reads mammograms for screening, Lunit SCOPE predicts immunotherapy response, and the Volpara acquisition (now Lunit International) added breast-screening AI sold directly to more than 3,000 US hospitals.
How it started
Founded in 2013 and traded on KOSDAQ, Lunit grew from research into cancer-screening software used by hospitals and drugmakers. In May 2025 it entered the US market by acquiring Volpara (now Lunit International), financing the deal with ₩171.5 billion of convertible bonds — a bet that growth would outrun the debt.
What happened
By early 2026 the CB put options had become a wall: with the share price down, CFO Park Hyeon-seong put the worst-case payout at about ₩197 billion, and institutions refused a smaller third-party placement while the risk stood. After an 18% share-price drop, Lunit announced its 'final capital raise' — a ₩250 billion shareholder rights offering at a 25% discount, paired with a 1:1 bonus issue — and a strategic pivot: revenue growing 40–50%, operating costs cut more than 20%, headcount already down 15%, and positive EBITDA targeted by end-2026, a year earlier than planned.
How it ended up
CEO Brandon Suh called it the first time in Lunit's 13-year history that profitability came before growth. The bet was that existing shareholders, not new lenders, would clear the overhang: in April 2026 the ₩211.5 billion offering closed 104.7% subscribed, with Atinum Investment taking about ₩30 billion, removing the put-option risk and the threat of administrative-stock designation; new shares were scheduled to list on May 15.
Background
Lunit is a Korean medical-AI company, founded in 2013, that sells software for cancer screening and oncology: Lunit INSIGHT reads mammograms, Lunit SCOPE predicts immunotherapy response, and the 2025 acquisition of Volpara (now Lunit International) added breast-screening AI and a direct channel to more than 3,000 US hospitals. The deal was financed with ₩171.5 billion of convertible bonds issued in May 2025.
By early 2026 the CBs' put options had become a wall: with the stock down, the worst-case payout CFO Park Hyeon-seong put at about ₩197 billion, and institutions refused to back a smaller third-party placement while the risk stood. After an 18% share-price drop, Lunit announced its 'final capital raise' — a ₩250 billion shareholder rights offering at a 25% discount, paired with a 1:1 bonus issue — and a strategic pivot: revenue growing 40–50%, operating costs cut more than 20%, headcount already down 15%, and positive EBITDA targeted by the end of 2026, a year earlier than planned.
CEO Brandon Suh called it the first time in Lunit's 13-year history that profitability came before growth. The bet was that existing shareholders, not new lenders, would clear the overhang: in April 2026 the ₩211.5 billion offering closed 104.7% subscribed, with Atinum Investment taking about ₩30 billion, removing the put-option risk and the threat of administrative-stock designation, with new shares scheduled to list on May 15.
What has to be true
- Convertible bonds with put options put a deadline on the stock: if the share price stayed low, investors could force repayment of roughly ₩197 billion.
- Third-party money would not touch Lunit while the put risk stood, so the only fix was a rights issue that let shareholders, not lenders, clear the balance sheet.
- Volpara was a long-term bet on a US direct channel to 3,000+ hospitals; the capital raise was the price of keeping that bet alive.
- Profitability targets gave the story an exit: cost cuts of 20% plus 40–50% revenue growth promised EBITDA breakeven within the same year.
What can be applied
Growth financed by put-option debt is a clock, not a runway: Lunit cleared the balance-sheet deadline by asking shareholders to subscribe instead of waiting for lenders to price the risk.
Aftermath
By late April 2026 the plan held: shareholders subscribed 104.7% of Lunit's ₩211.5 billion offering, Atinum invested about ₩30 billion, and management said the funds structurally remove the Volpara CB put risk and the administrative-stock concern. CEO Suh repeated that this was the final capital raise and that Lunit would prove EBITDA profitability by the end of 2026. Remaining risk is execution: dilution angered some holders, the targets depend on Volpara's US channel and SCOPE's pharma deals converting to recurring revenue, and the share price must rebuild trust the overhang destroyed.
Sources
- Lunit shifts to profitability-first strategy with ₩250 bil. rights offering
- Lunit Declares 'Final Capital Raise' with 250 Billion Won Rights Offering
- 'Shareholders Bet First'… Lunit Completes 211.5 Billion Won Capital Increase with 104.7% Subscription Rate
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card